Denali Therapeutics Inc.

DNLI

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 30, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
idursulfase	Phase 3	Mucopolysaccharidosis II	-
tividenofusp alfa	Phase 2	Mucopolysaccharidosis II	-
DNL126	Phase 2	Mucopolysaccharidosis Type IIIA	-
DNL593	Phase 2	Frontotemporal Dementia	-
BIIB122 225 mg	Phase 2	Parkinson Disease	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

Apr 30, 2026BIIB122 225 mg

Primary completion for BIIB122 225 mg trial (NCT06602193) in Parkinson Disease

Regulatory Approvals

DNLI News